Russian Heart Failure Journal 2011year Study of N-terminal subpeptide of brain natriuretic peptide in the diagnosis of CHF with the preserved systolic function of the left ventricle


To access this material please log in or register

Register Authorize
2011/

Study of N-terminal subpeptide of brain natriuretic peptide in the diagnosis of CHF with the preserved systolic function of the left ventricle

Borisov S. N., Gendlin G. E., Storozhakov G. I.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: NT-proBNP, left ventricle, systolic dysfunction of left ventricle, CHF

DOI: 10.18087/rhfj.2011.6.1615

Relevance. Significant part of patients with CHF have normal left ventricle ejection fraction (LVEF). Diagnosis of CHF with normal LVEF meets certain complexities due to its little specificity and poor expressiveness of clinical symptoms in such patients. As most of events take place in CHF patient’s organism at the highest physical load, it is considered reasonable to carry out the study of NT-proBNP concentration at the highest physical loading test for purposes of early diagnosis of CHF with normal LVEF. Purpose. Estimation on diagnostic significance of the study of NT-proBNP concentration at the highest physical load in patients with CHF and normal LVEF. Materials and methods. 30 patients with CHF with normal LVEF (EF >55 %) and 30 subjects of the reference group were studied. NT-proBNP serum concentrations at rest and at the highest treadmill physical load were determined and Doppler EchoCG was carried out in the studied patients. Results. NT-proBNP concentrations at rest and at load in patients with CHF with EF>55 % and healthy subjects were not statistically significantly different. Increase of NT-proBNP (d NT-proBNP) in the studied groups did not significantly differ, neither. At the same time percentage increase of NT-proBNP, which is ratio d NT-proBNP to NT-proBNP at rest, was statistically significant and notably higher in EF >55 % CHF group. With division of the studies patients into the groups depending on the physical load, higher NT-proBNP percentage increase corresponded to lower physical load.
  1. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эпидемиологические исследования сердечной недостаточности: состояние вопроса. Журнал Сердечная Недостаточность. 2002;3 (2): 57–58.
  2. Сторожаков Г.И., Гендлин Г.Е. Основные направления в лечении больных хронической сердечной недостаточностью. – Москва, Миклош, 2008. – 312с.
  3. Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Журнал Сердечная Недостаточность. 2003;4 (5):261–265.
  4. Беленков Ю. Н., Мареев В. Ю. Методы оценки тяжести ХСН и оценки результатов лечения или двадцать ответов на двадцать вопросов в двадцати иллюстрациях по результатам Российского многоцентрового исследования «ФАСОН». – Москва. 2002. – 23с.
  5. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93 (9):1137–1146.
  6. Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22 (4 Suppl A):6A-13A.
  7. Беленков Ю. Н., Агеев Ф. Т., Мареев В. Ю. Знакомьтесь: Диастолическая сердечная недостаточность. Журнал Сердечная недостаточность. 2000;1 (2):40–44.
  8. Cleland JG, Tendera M, Adamus J et al. PEP–CHF Investigators The pe­rindopril in elderly people with chronic heart failure (PEP–CHF) study. Eur Heart J. 2006;27 (19):2338–2345.
  9. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362 (9386):759–766.
  10. Januzzi JL Jr. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006;73 (2):149–152, 155–157.
  11. Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24 (19):1735–1743.
  12. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predict treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37 (2):386–391.
  13. Knudsen CW, Omland T, Clopton P et al. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med. 2004;116 (6):363–368.
  14. Cabanes L, Richaud-Thiriez B, Fulla Y et al. Brain natriuretic peptide blood le­vels in the differential diagnosis of dyspnea. Chest. 2001;120 (6):2047–2050.
  15. Maisel AS, Morrison K, Harrison A et al. B-natriuretic peptide differentiates cardiac from pulmonary causes of dyspnea. Eur Heart J. 2001;22:922.
  16. Kruger S, Graf J, Breuer С et al. High brain natriuretic peptide levels are associated with decreased exercise capacity in patients with chronic heart failure. Eur Heart J. 2001;22:306.
  17. Lainchbury JG, Swanney MP, Beckert L, Troughton RW. Change in plasma brain natriuretic peptide during exercise is an important predictor of survival in systolic heart failure. Eur Heart J. 2001;22:2073.
  18. Cowie MR. BNP: soon to become a routine measure in the care of patients with heart failure? Heart. 2000 Jun; 83 (6):617–618.
  19. Murdoch D, McDonagh T, Byrne J et al. Titration of vasodilator therapy in chronic heart failure acording to plasma brain natriuretic peptide concentration: randomized comparison of the hemodinamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138 (6 Pt 1):1126–1132.
  20. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  21. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26 (11):1115–1140.
  22. Hunt SA, Abraham WT, Chin MH. ACC / AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46 (6):e1–82.
  23. Волкова С. Ю. Диагностические возможности нейрогуморальных медиаторов в определении систолической дисфункции левого желудочка у больных ИБС с сердечной недостаточностью. Журнал Сердечная недостаточность. 2008;9 (1):25–30.
  24. Luchner A, Muders F, Dietl O et al. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res. 2001;51 (3):601–607.
  25. Сторожаков Г. И., Гендлин Г. Е., Самсонова Е. В. и др. Методики исследования качества жизни у больных с хронической недостаточностью кровообращения. Сердечная недостаточность. 2000;1 (2):74–80.
  26. Аронов Д. М., В. П. Лупанов Функциональные пробы в кардиологии, 2‑е изд. – М.: МЕДпресс-информ, 2002. – 295 с.
  27. Greenberg B, Barnard D, Narayan M, Teerlink J. Management of Heart Failure. – Wiley-Blackwell, 2010. – 395 P.
  28. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005;111 (18):2306–2312.
  29. Yu CM, Lin H, Yang H et al. Progression of systolic abnormalities in patients with «isolated» diastolic heart failure and diastolic dysfunction. Circulation. 2002;105 (10):1195–1201.
  30. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res. 2004;94 (12):1533–1542.
  31. Rihal CS, Nishimura RA, Hatle LK et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994;90 (6):2772–2779.
  32. Redfield MM, Kitzman DW. Heart failure: a rose by any other name? Congest Heart Fail. 2006;12 (3):166–168.
  33. Mottram PM, Haluska BA, Marwick TH. Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload. Am Heart J. 2004 Aug; 148 (2):365–370.
  34. Paraskevaidis IA, Tsougos E, Varounis C et al. Exercise-induced changes of B-type natriuretic peptide uncover the unknown coronary artery disease in patients with chest pain and normal left ventricular systolic function. Eur J Cardiovasc Prev Rehabil. 2011;18 (1):72–78.
  35. Kazanegra R, Cheng V, Garcia A et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for de­compensated heart failure: a pilot study. J Card Fail. 2001;7 (1):21–29.
  36. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6 (3):261–268.
  37. Maeda K, Tsutamoto T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135 (5 Pt 1):825–832.
Borisov S.N., Gendlin G.E., Storozhakov G.I. Study of N-terminal subpeptide of brain natriuretic peptide in the diagnosis of CHF with the preserved systolic function of the left ventricle. Russian Heart Failure Journal. 2011;12(6):344-349.

To access this material please log in or register

Register Authorize
Ru En